Revolution Medicines, Inc. reiterated earnings guidance for the full year 2024. The company is reiterating its projected full year 2024 GAAP net loss to be between $480 million and $520 million, which includes estimated non-cash stock-based compensation expense of between $70 million and $80 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.62 USD | -2.82% | -4.26% | +34.66% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+34.66% | 6.37B | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- RVMD Stock
- News Revolution Medicines, Inc.
- Revolution Medicines, Inc. Reiterates Earnings Guidance for the Full Year 2024